@phdthesis{Hauck2005,
  author    = {Hauck, Fabian},
  title     = {Regulation des Blimp1-Promotors durch die Transkriptionsfaktoren C/EBP-Beta und NFATc1 in T-Lymphozyten},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-16092},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2005},
  abstract  = {Das murine Blimp1 (B lymphocyte-induced maturation protein) und sein humanes Homolog PRDI-BF1 (positive regulatory domain I binding factor 1) sind als terminale Differenzierungsfaktoren der myeloischen Reihe und der B-Lymphozyten (BCs) beschrieben worden. {\"U}ber direkte sequenzspezifische Promotorbindung und epigenetische Modifikationen greifen sie gr{\"o}ßtenteils reprimierend in die Expression einer Vielzahl von Genen ein und werden dabei funktionell mit einer niedrigen Proliferationsrate und einem hohen Grad an Zelldifferenzierung und Apoptose in Zusammenhang gebracht. Im Zuge dieser Arbeit konnte gezeigt werden, dass Blimp1 auch in der zweiten lymphatischen Zellreihe, also in den T-Lymphozyten (TCs) und hier insbesondere in den Subtypen der T-Helfer-2-Zellen (CD4+ TH2), der CD4+ T-Ged{\"a}chtniszellen (CD4+ TMem) und der regulatorischen TCs (CD4+ CD25+ TReg) exprimiert wird. Die gefundene Blimp1-Expression ist nicht konstitutiv. Vielmehr wird das Blimp1-Gen {\"u}ber T-Zellrezeptorsignale - {\"u}ber die Proteinkinase C (PKC) und den Anstieg freier intrazellul{\"a}rer Ca2+-Konzentrationen - verst{\"a}rkend {\"u}ber den Interleukin-6-Rezeptor-pathway, und {\"u}ber die Aktivit{\"a}t des Transkriptionsfaktors C/EBP\&\#946; (CCAAT/enhancer-binding protein) allein induziert. Die Transaktivierung des TATA-boxlosen Blimp1-Promotors (ca. 1 kb) durch C/EBP\&\#946; wird st{\"a}rker {\"u}ber dessen proximale H{\"a}lfte vermittelt, an der jedoch keine direkte Bindung des Transkriptionsfaktors nachzuweisen ist, und scheint somit indirekt zu sein. Im Gegensatz dazu bindet das C/EBP\&\#946;-Protein im schw{\"a}cher transaktivierenden distalen Blimp1-Promotorbereich direkt an eine kombinierte, der P1/Pu-bB-des IL-4-Promotors {\"a}hnliche NFAT/C/EBP-Bindungssequenz. Die C/EBP-Bindungsstelle liegt hierbei in direkter Nachbarschaft zum NFAT-(nuclear factor of activated T cells) Bindungsmotiv. Auch NFATc1 bindet direkt, entwickelt aber kein transaktivierendes Potential sondern reprimiert vielmehr die durch C/EBP\&\#946;-vermittelte Transaktivierung.},
  language  = {de}
}
@phdthesis{Akimzhanov2005,
  author    = {Akimzhanov, Askar M.},
  title     = {Epigenetic repression of the NFATc1 transcription factor in human lymphomas},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-12921},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2005},
  abstract  = {We examined the regulation of NFATc1 in different lymphomas and observed an inversed correlation between the methylation status and expression of NFATc1. Our data demonstrate that aberrant DNA methylation associated with chromatin remodeling within nfatc1 locus is a major mechanism for the repression of NFATc1 expression, suggesting that the DNA methylation-mediated transcriptional silencing of NFATc1 may be a critical event in the tumorogenesis of ALCLs and cHLs. Furthermore, the DNA methylation of human nfatc1 promoter region could be used as a novel biomarker of tumor progression. Our results indicate a close link between the loss of immunoreceptor signaling and NFATc1 expression in human lymphomas. For both ALCLs and cHLs, defects in immunoreceptor signaling have been described which result in a loss of receptor-mediated gene expression programs (Schwering et al., 2003; Bonzheim et al., 2004; Marafioti et al., 2004). In T cells, one indicator gene of these programs appears to be the nfatc1 gene whose expression is controlled by TCR signals (Chuvpilo et al., 2002a). In contrast, in T cells NFATc1 expression is unaffected by TCR signals, and NFATc2 was found to be expressed at normal levels in ALCLs and cHLs (L.K., unpubl. data). Moreover, the activity of NF-kappaB factors which can bind to certain NFAT binding sites and share a distantly-related DNA binding domain with NFATs is strongly elevated in cHL cells (Bargou et al., 1997; Hinz et al., 2001; Hinz et al., 2002) suggesting that NFATs and NF-kappaBs exert very different effects on generation and maintenance of Hodgkin's lymhomas. However, it should be mentioned that in Burkitt's and further B cell lymphomas in which NFATc1 proteins are strongly expressed and controlled by receptor signals (Kondo et al., 2003), they could exert a promoting function in tumor development. The genes of p53 family members p63 and p73 are prominent examples for mammalian genes whose products can act both as oncoproteins and tumor suppressor genes (Hibi et al., 2000; Stiewe and Putzer, 2002), and it is likely that more genes exist which encode both tumor suppressors and oncoproteins. It remains to be shown whether the nfatc1 gene is one of them.},
  subject      = {Lymphom},
  language  = {en}
}